Table 3.
Baseline characteristics of the randomized controlled trial population (mild and moderate myocardial iron loading) vs. open-label combination therapy population (severe myocardial iron loading). Values and abbreviations presented as in table 1.
| Mild-moderate siderosis | Severe siderosis | p-value | |
|---|---|---|---|
| RCT | Longitudinal trial | ||
| Number | 65 | 15 | - |
| Age (years) | 28.8 ± 4.7 | 27.8 ± 4.8 | 0.5 |
| Gender (male) | 27 (41.5%) | 6 (40.0%) | 0.9 |
| Body surface area | 1.55 ± 0.15 | 1.56 ± 0.13 | 0.8 |
| Heart rate | 79 ± 13 | 97 ± 18 | < 0.01 |
| Deferoxamine (mg/kg/day) | 40.6 ± 13.5 (5 days/week) |
40.7 ± 12.0 (5 days/week) |
0.9 |
| CMR measures | |||
| Myocardial T2* | 12.0 (0.13) | 6.0 (0.09) | N/A |
| Liver T2* | 4.5 (0.57) | 2.9 (0.67) | 0.06 |
| RVEDV (mL) | 130.7 ± 32.4 | 146.7 ± 35.1 | 0.2 |
| RVESV (mL) | 52.4 ± 17.8 | 76.5 ± 27.6 | < 0.01 |
| RVEF (%) | 60.6 ± 7.1 | 49.0 ± 9.4 | < 0.01 |
| Echo measures | |||
| PAP (mmHg) | 21.6 ± 5.2 | 22.0 ± 5.9 | 0.8 |
| Blood measures | |||
| Hepatitis C positive | 49 (75%) | 11 (73%) | 0.9 |
| Serum ferritin (μg/L) | 1472 (0.11) | 2057 (0.08) | 0.1 |
| BNP (pmol/L) | 15.0 (7.1, 28.8) | 26.0 (15.6, 40.5) | 0.01 |
| Cardiac medication | |||
| Any | 13 (20%) | 7 (47%) | 0.03 |
| Digoxin | 7 (11%) | 4 (27%) | 0.1 |
| ACEi/ARB | 13 (20%) | 7 (47%) | 0.03 |
| Diuretics | 8 (12%) | 4 (27%) | 0.2 |